6. Actavis

Total: $250.5 million
TV: $116.6 million
Magazine: $129.3 million
Newspaper: $4.5 million
Radio: $35,900

Actavis ($ACT) is the only pharma company in the top 10 that didn't spend the bulk of its budget on TV ads. Instead, the Dublin-based drugmaker, which recently completed its $70.5 billion acquisition of Allergan and is awaiting shareholder approval of an official name change to Allergan, spent more than half of its budget (52%) on magazine advertising.

Allergan's well-known cosmetic pharmaceutical brand Botox--also approved for medical uses such as migraines, muscle spasms and incontinence--was well-represented in both TV and magazine advertising across indications. So was chronic dry eye treatment Restasis and injectable Juvederm. Meanwhile, Actavis' irritable bowel med Linzess, and its illustrative twisted blue rope over bare stomachs, became a familiar advertising image in 2014, along with oral contraceptive Lo Loestrin magazine ads.

The combined company Actavis/Allergan is expected to generate $23 billion in revenues this year, according to an Actavis press release.

For more:
Actavis CEO: We may be big, but we don't want to be Big Pharma
Actavis revs up new commercial team for post-Allergan-merger sales race
Analysts: Actavis-Allergan deal could create a marketing superpower
Allergan's pipeline in a drug, Botox could keep new marketing twists coming

6. Actavis

Suggested Articles

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.

How much are lawsuits hurting J&J's brand? The New Jersey drugmaker has lost half a billion dollars in brand value over the past year, a report says.